Hossein Amini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hossein Amini has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Omid Moradi
Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
2 shared publications Alireza Dastan
Ernest and Julio Gallo Management Program, School of Engineering University of California, Merced, United States
1 shared publication- Alireza Manafi Rasi
Musculoskeletal Injuries Research Center Shahid Beheshti University of Medical Sciences Tehran Iran
1 shared publication - Alireza Zali
Functional Neurosurgery Research Center, Research Institute of Functional Neurosurgery, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication Asghar Rahmani
General Physician, School of Medicine, Ilam University of Medical Science, Ilam, Iran
1 shared publication- Audrey Tolouian
The University of Texas at El Paso School of Nursing, El Paso, Texas, USA
1 shared publication
Latest Publications
- Open Access
- 26 August 2024
- Published by Brieflands in Journal of Comprehensive Pediatrics
- Vol. 15 (4)
A Cross-Sectional Investigation on Drug-Drug Interactions in Prescriptions of Pediatric Outpatient Clinics at a Referral Center in Southern Iran
Background: Drug interactions can lead to treatment failure, the occurrence of side effects, complicate the clinical course and severity of the disease, and prolong hospitalization duration. Pediatrics are particularly vulnerable to drug interactions. Objectives: This study aims to evaluate prescribed medications and the incidence of drug interactions in pediatric patients. Methods: This study was conducted as a cross-sectional investigation. Over nine months, we evaluated pediatric patients referred to Bandar Abbas Children’s Hospital, affiliated with Hormozgan University of Medical Sciences, who received outpatient treatment services. The medications these patients received were assessed for drug interactions. Only interactions with clinical importance (i.e., category C-D-X) were considered. Using the Lexi-Interact online database, the prescribed drugs were evaluated in terms of the number and type of potential drug-drug interactions. Results: A total of 1011 patients were included in the study based on the determined criteria. The mean age was 4.52 ± 0.11 years, and the male-to-female ratio was 1.2:1. More than two-thirds of the patients were seen by general physicians. Among all participants, 26.7% had at least one clinically significant interaction in their prescriptions. Furthermore, 309 interactions were identified, of which 6.39% were of significant severity, and 93.61% were of moderate severity. The risk rating of C was the most common interaction, followed by X and D (87.7%, 7.4%, and 4.8%, respectively). Regarding reliability, 0.30% had fair reliability, 64.20% had good reliability, and 35.50% had excellent reliability ratings. Patients with underlying conditions were at increased risk of interaction occurrence (OR = 1.8, P = 0.008). Conclusions: Drug interactions with high clinical significance were identified at a high prevalence rate. These interactions can have significant consequences. Pharmacists and physicians play an important role in identifying and managing drug-drug interactions.
- 26 August 2024
- Published by Brieflands in Journal of Comprehensive Pediatrics
- Vol. 15 (4)
Open AccessA Cross-Sectional Investigation on Drug-Drug Interactions in Prescriptions of Pediatric Outpatient Clinics at a Referral Center in Southern Iran
Background: Drug interactions can lead to treatment failure, the occurrence of side effects, complicate the clinical course and severity of the disease, and prolong hospitalization duration. Pediatrics are particularly vulnerable to drug interactions. Objectives: This study aims to evaluate prescribed medications and the incidence of drug interactions in pediatric patients. Methods: This study was conducted as a cross-sectional investigation. Over nine months, we evaluated pediatric patients referred to Bandar Abbas Children’s Hospital, affiliated with Hormozgan University of Medical Sciences, who received outpatient treatment services. The medications these patients received were assessed for drug interactions. Only interactions with clinical importance (i.e., category C-D-X) were considered. Using the Lexi-Interact online database, the prescribed drugs were evaluated in terms of the number and type of potential drug-drug interactions. Results: A total of 1011 patients were included in the study based on the determined criteria. The mean age was 4.52 ± 0.11 years, and the male-to-female ratio was 1.2:1. More than two-thirds of the patients were seen by general physicians. Among all participants, 26.7% had at least one clinically significant interaction in their prescriptions. Furthermore, 309 interactions were identified, of which 6.39% were of significant severity, and 93.61% were of moderate severity. The risk rating of C was the most common interaction, followed by X and D (87.7%, 7.4%, and 4.8%, respectively). Regarding reliability, 0.30% had fair reliability, 64.20% had good reliability, and 35.50% had excellent reliability ratings. Patients with underlying conditions were at increased risk of interaction occurrence (OR = 1.8, P = 0.008). Conclusions: Drug interactions with high clinical significance were identified at a high prevalence rate. These interactions can have significant consequences. Pharmacists and physicians play an important role in identifying and managing drug-drug interactions.
- Open Access
- 1 June 2024
- Published by Brieflands in International Journal of Cardiovascular Practice
- Vol. 9 (1)
Evaluating the Predictive Value of a Cardiac Perfusion Scan for Cardiac Events in Chronic Kidney Disease
Background: Cardiovascular diseases are among the leading causes of morbidity and mortality in chronic kidney disease (CKD) patients. Therefore, predicting cardiac events in CKD patients is essential. Objectives: The present study aims to evaluate the predictive value of single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) in patients with different stages of CKD. Methods: Consecutive CKD patients with an estimated glomerular filtration rate (eGFR
- 1 June 2024
- Published by Brieflands in International Journal of Cardiovascular Practice
- Vol. 9 (1)
Open AccessEvaluating the Predictive Value of a Cardiac Perfusion Scan for Cardiac Events in Chronic Kidney Disease
Background: Cardiovascular diseases are among the leading causes of morbidity and mortality in chronic kidney disease (CKD) patients. Therefore, predicting cardiac events in CKD patients is essential. Objectives: The present study aims to evaluate the predictive value of single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) in patients with different stages of CKD. Methods: Consecutive CKD patients with an estimated glomerular filtration rate (eGFR
- Open Access
- 7 November 2022
- Published by Brieflands in Jundishapur Journal of Microbiology
- Vol. 15 (8)
Bromhexine for Post-exposure COVID-19 Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial
Background: Limited medications are available for post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) infection. Whether bromhexine can prevent or mitigate symptomatic infection after virus exposure is undetermined. Objectives: We aimed to evaluate bromhexine's effect on preventing COVID-19 after close contact exposure. Methods: A multi-center randomized, double-blind, placebo-controlled clinical trial was conducted on 372 adults (≥ 18 years) who had close contact within four days with a household member with confirmed COVID-19. They were randomly assigned to receive bromhexine 8 mg (n = 187) or placebo (n = 185) three times a day for two weeks. The primary outcome was the incidence of symptomatic COVID-19. Secondary outcomes included hospitalization or death, confirmed COVID-19 by Polymerase Chain Reaction (PCR) in symptomatic patients, and adverse drug reactions. Results: The incidence of symptomatic COVID-19 was significantly lower in individuals who received bromhexine than in those who received the placebo (16 [8.6%] vs. 34 [18.4%], relative risk = 0.47, P = 0.005). PCR confirmation was reported in 13 (7.0%) and 26 (14.1%) individuals in the bromhexine and placebo groups, respectively (P = 0.025), with a relative risk reduction of 50%. The hospitalization rate, death, and medication side effects did not vary significantly between the bromhexine and placebo arms. Conclusions: Bromhexine is an effective, non-invasive, affordable agent with a low side-effect profile to prevent symptomatic COVID-19. Early use of bromhexine potentially provides another layer of protection; hence, it can play a role in controlling the pandemic.
- 7 November 2022
- Published by Brieflands in Jundishapur Journal of Microbiology
- Vol. 15 (8)
Open AccessBromhexine for Post-exposure COVID-19 Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial
Background: Limited medications are available for post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) infection. Whether bromhexine can prevent or mitigate symptomatic infection after virus exposure is undetermined. Objectives: We aimed to evaluate bromhexine's effect on preventing COVID-19 after close contact exposure. Methods: A multi-center randomized, double-blind, placebo-controlled clinical trial was conducted on 372 adults (≥ 18 years) who had close contact within four days with a household member with confirmed COVID-19. They were randomly assigned to receive bromhexine 8 mg (n = 187) or placebo (n = 185) three times a day for two weeks. The primary outcome was the incidence of symptomatic COVID-19. Secondary outcomes included hospitalization or death, confirmed COVID-19 by Polymerase Chain Reaction (PCR) in symptomatic patients, and adverse drug reactions. Results: The incidence of symptomatic COVID-19 was significantly lower in individuals who received bromhexine than in those who received the placebo (16 [8.6%] vs. 34 [18.4%], relative risk = 0.47, P = 0.005). PCR confirmation was reported in 13 (7.0%) and 26 (14.1%) individuals in the bromhexine and placebo groups, respectively (P = 0.025), with a relative risk reduction of 50%. The hospitalization rate, death, and medication side effects did not vary significantly between the bromhexine and placebo arms. Conclusions: Bromhexine is an effective, non-invasive, affordable agent with a low side-effect profile to prevent symptomatic COVID-19. Early use of bromhexine potentially provides another layer of protection; hence, it can play a role in controlling the pandemic.
- Open Access
- 10 October 2022
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 42 (2) , 139-144
Evaluating the efficacy and safety of rivaroxaban as a warfarin alternative in chronic thromboembolic pulmonary hypertension patients undergoing pulmonary endarterectomy: A randomized clinical trial
- 10 October 2022
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 42 (2) , 139-144
Open AccessEvaluating the efficacy and safety of rivaroxaban as a warfarin alternative in chronic thromboembolic pulmonary hypertension patients undergoing pulmonary endarterectomy: A randomized clinical trial